Tissue Inhibitor of Metalloproteinase-2 as a Multifunctional Molecule of Which the Expression Is Associated with Adverse Prognosis of Patients with Urothelial Bladder Carcinomas

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5573-5581

  Gakiopoulou, Hariklia ^a   Nakopoulou, Lydia ^a   Siatelis, Argyris ^a   Mavrommatis, Ioannis ^a   Panayotopoulou, Effie G ^a   Tsirmpa, Ioanna ^a   Stravodimos, Constantinos ^a   Giannopoulos, Aris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; HORSERADISH PEROXIDASE; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; POLYCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADULT; AGE; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME REGULATION; EVALUATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEX DIFFERENCE; STROMA CELL; SURVIVAL RATE;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0344198120     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Liotta, L. A. Tumor invasion and metastasis-role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res., 46: 1-7, 1986.
2. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
3. Nagase, H. Activation mechanisms of matrix metalloproteinases. Biol. Chem., 378: 151-160, 1997.
4. Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 74: 111-122, 1997.
5. Docherty, A. J. P., and Murphy, G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann. Rheum. Dis., 49: 469-479, 1990.
6. Stetler-Stevenson, W. G., Krutzsch, H. C., and Liotta, L. A. Tissue inhibitor of metalloproteinase-2 (TIMP-2). J. Biol. Chem., 264: 17374-17378, 1989.
7. Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, S., and He, C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc. Nat. Acad. Sci. USA, 86: 8207-8211, 1989.
8. Willenbrock, F., Crabbe, T., Slocombe, P. M., Sutton, C. W., Docherty, A. J., Cockett, M. I., O'Shea, M., Brocklehurst, K., Phillips, I. R., and Murphy, G. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry, 32: 4330-4337, 1993.
9. Yu, A. E., Hewitt, R. E., Kleiner, D. E., and Stetler-Stevenson, W. G. Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem. Cell Biol., 74: 823-831, 1996.
10. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. Mechanism of cell surface activation of 72 kDa type collagenase: isolation of the activated form of the membrane metalloproteinase. J. Biol. Chem., 270: 5331-5338, 1995.
11. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. R. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
12. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A., Ohkawa, J., Kamidono, S., and Nakajima, M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (Phila.), 78: 2379-2387, 1996.
13. Grigioni, W. F., D'Errico, A., Fortunato, C., Fiorentino, M., Mancini, A. M., Stetler-Stevenson, W. G., Sobel, M. E., Liotta, L. A., Onisto, M., and Garbisa, S. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod. Pathol., 7: 220-225, 1994.
14. Onisto, M., Riccio, M. P., Scannappieco, P., Canazzo, C., Griggio, L., Spina, M., Stetler-Stevenson, W. G., and Garbisa, S. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int. J. Cancer, 63: 621-626, 1995.
15. Ring, P., Johansson, K., Hoyhtya, M., Rubin, K., and Lindmark, G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumor stage. Br. J. Cancer, 76: 805-8011, 1997.
16. Ara, T., Fukuzawa, M., Kusafuka, T., Komoto, Y., Oue, T., Inoue, M., and Okada, A. Immunohistochemical expression of MMP-2, MMP-9 and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J. Pediatr. Surg., 33: 1272-1278, 1998.
17. Nemeth, J. A., and Goolsby, C. L. TIMP-2, a growth stimulatory protein from SV40-transformed human fibroblasts. Exp. Cell Res., 207: 376-282, 1993.
18. Stetler-Stevenson, W. G., Bersch, N., and Golde, D. W. Tissue inhibitor of metalloproteinase-2 has erythroid-potentiating activity. FEBS Lett., 296: 231-234, 1992.
19. Corcoran, M. L., Hewitt, R. E., Kleiner, D. E., Jr., and Stetler-Stevenson, W. G. MMP-2: Expression, activation and inhibition. Enzyme Protein, 49: 7-19, 1996.
20. Li, G., Fridman, R., and Kim, H. R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res., 59: 6267-6275, 1999.
21. Remacle, A., McCarthy, K., Noël, A., Maguire, T., McDermott, E., O'Higgins, N., Foidart, J. M., and Duffy, M. J. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer, 89: 118-121, 2000.
22. Murashige, M., Miyahara, M., Shiraishi, N., Saito, T., Kohno, K., and Kobayashi, M. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn. J. Clin. Oncol., 26: 303-309, 1996.
23. Ree, A. H., Flyrenes, V. A., Berg, J. P., Maelandsmo, G. M., Nesland, J. M., and Fodstad, Y. High levels of mRNA for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of metastases. Clin. Cancer Res., 3: 1623-1628, 1997.
24. Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M., and Kagawa, S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (Phila.), 82: 1359-1366, 1998.
25. Davidson, B., Goldberg, I., Kopolovic, J., Lerner-Geva, L., Gotlieb, W. H., Ben-Baruch, G., and Reich, R. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol., 73: 372-382, 1999.
26. Mostofi, F. K., and Sobin, L. H. Histologic Typing of Urinary Bladder Tumors. Geneva: WHO, 1973.
27. International Union Against Cancer (Union Internationale Contre le Cancer) TNM Atlas. P. Hermanek, R. V. P. Hutter, L. H. Sobin, G. Wagner, and C. H. Wittekind (eds.), (corrected Second Printing 1999), pp. 309-314. Berlin, Heidelberg, New York: Springer-Verlag, 1997.
28. Hsu, S. M., Raine, L., and Fanger, H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
29. Nakopoulou, L., Katsarou, S., Giannopoulou, I., Alexandrou, P., Tsirmpa, I., Panayotopoulou, E., Mavrommatis, J., and Keramopoulos, A. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod. Pathol., 15: 26-34, 2002.
30. Nakopoulou, L., Vourlakou, Ch., Zervas, A., Tzonou, A., Gakiopoulou, H., and Dimopoulos, M. A. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum. Pathol., 29: 146-154, 1998.
31. Nakopoulou, L., Constantinides, C., Papandropoulos, J., Theodoropoulos, G., Tzonou, A., Giannopoulos, A., Zervas, A., and Dimopoulos, C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology, 46: 334-340, 1995.
32. Hewitt, R., and Danø, K. Stromal cell expresssion of components of matrix-degrading protease systems in human cancer. Enzyme Protein, 49: 163-173, 1996.
33. Hoyhtya, M., Frieman, R., Komarek, D., Porter-Jordan, K., Stetler-Stevenson, W. G., Liotta, L. A., and Liang, C. M. Immunohistochemical localization of matrix metallproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer, 56: 500-505, 1994.
34. Poulsom, R., Pignatelli, M., Stetler-Stevenson, W. G., Liotta, L. A., Wright, P. A., Jeffery, R. E., Longcroft, J. M., Rogers, L., and Stamp, G. W. Stromal expression of 72-kD type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol., 141: 389-396, 1992.
35. Poulsom, R., Hanby, A. M., Pignatelli, M., Jeffery, R. E., Longcroft, J. M., Rogers, L., and Stamp, G. W. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J. Clin. Pathol., 46: 429-436, 1993.
36. Visscher, D. W., Hoyhtya, M., Ottosen, S. K., Liang, C. M., Sarkar, F. H., Crissman, J. D., and Fridman, R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer, 59: 339-344, 1994.
37. Naylor, M. S., Stamp, G. W. H., Davies, B., and Balkwill, F. R. Expression and activity of MMPs and their regulators in ovarian cancer. Int. J. Cancer, 58: 50-56, 1994.
38. Michael, M., Babic, B., Khokha, R., Tsao, M., Ho, J., Pintilie, M., Leco, K., Chamberlain, D., and Shepherd, F. A. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol., 17: 1802-1808, 1999.
39. Grignon, D. J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., Pontes, J. E., Crissman, J. C., and Fridman, R. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 1: 1654-1659, 1996.
40. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2. J. Cell Sci., 107: 2373-2379, 1994.
41. Corcoran, M. L., and Stetler-Stevenson, W. G. Tissue inhibitor of metalloproteinase-2 stimulates fibroblasts proliferation via a cAMP-dependent mechanism. J. Biol. Chem., 270: 13453-13459, 1994.
42. Tanaka, K., Iwamoto, Y., Ito, Y., Ishbashi, T., Nakopoulou, Y., Sekiguchi, M., and Sugioka, Y. Cyclic AMP resulted synthesis of the tissue inhibitors of metalloproteinase suppresses the invasive potential of human fibrosarcoma cell line HT1080. Cancer Res., 55: 2927-2935, 1995.
43. Avalos, B. R., Kaufman, S. E., Tononaga, M., Williams, R. E., Golde, D. W., and Gasson, J. C. K562 cells produce and respond to human erythroid-potentiating activity. Blood, 71: 1720-1725, 1988.
44. Bertaux, B., Hornebeck, W., Eisen, A. Z., and Dubertret, L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Investig. Dermatol., 97: 679-685, 1991.
45. Furihata, M., Sonobe, H., and Ohtsuki, Y. Detection of 53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J. Pathol., 178: 133-139, 1996.
46. Naruo, S., Kanayama, H., Aki, M., and Kagawa, S. Gene expressions of type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers. Nippon Hinyokika Gakkai Zasshi, 84: 841-850, 1993.
47. Hara, I., Miyake, H., Hara, S., Arakawa, S., and Kamidono, S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol., 165: 1769-1772, 2001.
48. Oberg, A., Hoyhtya, M., Tavelin, B., Stenling, R., and Lindmark, G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res., 20: 1085-1091, 2000.